

## Notes to Authors

For a full and complete Guide for Authors, please go to:  
<http://www.elsevier.com/locate/AVR>

### Electronic Submission

Authors should submit their articles electronically via the Elsevier Editorial System (EES) page of this journal <http://ees.elsevier.com/AVR>. The system automatically converts source files to a single Adobe Acrobat PDF version of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail and via the Author's homepage, removing the need for a hard-copy paper trail.

### Language services

Authors who require information about language editing and copyediting services pre- and post-submission please visit <http://www.elsevier.com/languageediting> or our customer support site at <http://epsupport.elsevier.com>.

### Author enquiries

For enquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage at <http://www.elsevier.com/locate/AVR>. You can track accepted articles at <http://www.elsevier.com/trackarticle> and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more.

Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.

***Antiviral Research* has no page charges**

**Sponsored Supplements and/or Commercial Reprints:** For more information please contact Elsevier Life Sciences Commercial Sales, Radarweg 29, 1043 NX Amsterdam, The Netherlands; phone: (+31) (20) 485 2939/2059; e-mail: [LSCS@elsevier.com](mailto:LSCS@elsevier.com)

**Advertising information:** If you are interested in advertising or other commercial opportunities please e-mail [Commercialsales@elsevier.com](mailto:Commercialsales@elsevier.com) and your enquiry will be passed to the correct person who will respond to you within 48 hours.

**USA mailing notice:** *Antiviral Research* (ISSN 0166-3542) is published monthly by Elsevier B.V. (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Periodical postage paid at Rahway NJ and additional mailing oces.

**USA POSTMASTER:** Send change of address: *Antiviral Research*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

**AIRFREIGHT AND MAILING** in the USA by Mercury International Limited, 365, Blair Road, Avenel, NJ 07001.

♾ The paper in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

Printed by Henry Ling Ltd, The Dorset Press, Dorchester, UK